Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acromegaly - evolving strategies.

Vera Popovic1

  • 1Neuroendocrine Unit, Institute of Endocrinology, University Clinical Center, Belgrade Serbia. popver@Eunet.Yu

Pediatric Endocrinology Reviews : PER
|January 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study.

The lancet. Diabetes & endocrinology·2025
Same author

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

European journal of endocrinology·2025
Same author

Correction: Genome‑wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.

Acta neuropathologica·2025
Same author

Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.

Acta neuropathologica·2024
Same author

Editorial: Towards targeting prolactin signaling in human diseases: stimulate or inhibit?

Frontiers in endocrinology·2023
Same author

Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?

Endocrine oncology (Bristol, England)·2023
Same journal

Letters to the Editor: Why are Children with Klinefelter Syndrome Tall?

Pediatric endocrinology reviews : PER·2020
Same journal

Genetic and Environmental Factors in the Pathophysiology of Hashimoto's Thyroiditis.

Pediatric endocrinology reviews : PER·2020
Same journal

New Insights into Pheochromocytoma Biology: the Role of the Insulin - Like Growth Factor 1 (IGF1) System.

Pediatric endocrinology reviews : PER·2020
Same journal

Use of Growth Hormone Treatment in Skeletal Dysplasia - A Review.

Pediatric endocrinology reviews : PER·2020
Same journal

Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease.

Pediatric endocrinology reviews : PER·2020
Same journal

Impact of Childhood Obesity on Bone Metabolism.

Pediatric endocrinology reviews : PER·2020
See all related articles

Growth hormone (GH)-cell adenomas cause acromegaly, a disabling disease. New therapies aim to normalize GH levels and restore normal life expectancy for patients.

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Growth hormone (GH)-cell adenomas are benign pituitary tumors causing chronic high GH output.
  • Acromegaly, resulting from these tumors, is a disfiguring and disabling condition with reduced life expectancy.
  • Hereditary forms are rare; most GH-cell adenomas causing acromegaly are sporadic.

Purpose of the Study:

  • To review current treatments for acromegaly and evolving therapeutic strategies.
  • To highlight challenges in assessing disease activity and defining cure post-treatment.
  • To discuss the goal of achieving normal life expectancy in acromegaly patients.

Main Methods:

  • Review of current therapeutic approaches including surgery, radiotherapy, and medical therapy.
  • Discussion of evolving strategies such as GH receptor antagonists, dopamine agonists, and somatostatin analogs.

Related Experiment Videos

  • Examination of diagnostic challenges and consensus definitions for biochemical cure.

    • Main Results:

    • Treatment choice for acromegaly depends on patient factors and disease severity.
    • Biochemical cure is defined by normalized GH and IGF-I levels.
    • New therapeutic strategies show promise in optimizing acromegaly control.

    Conclusions:

    • Effective control of acromegaly requires tailored treatment strategies.
    • Defining and achieving biochemical cure is crucial for patient management.
    • Evolving therapies aim to normalize life expectancy for acromegaly patients.